Inspire Investing’s Acadia Pharmaceuticals ACAD Stock Holding History

Inspire Investing’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26,401	Closed	-$439K	–	787
2021 Q3	$439K	Buy	+26,401	New	+$509K	0.06%	234
2020 Q2	–	Sell	-191	Closed	-$8K	–	489
2020 Q1	$8K	Buy	+191	New	+$7.87K	﹤0.01%	717

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Inspire Investing's ACAD Position: Q4 2021 in Review

Inspire Investing sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 26,401 shares — an estimated $439K sold.

Inspire Investing first reported a position in ACAD in Q1 2020 and held it in 2 quarters. The position peaked at $439K in Q3 2021. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

Inspire Investing reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Inspire Investing sold 26,401 Acadia Pharmaceuticals shares in Q4 2021, an estimated $439K.
Inspire Investing first reported a position in Acadia Pharmaceuticals in Q1 2020 and held it in 2 quarters.
Inspire Investing's Acadia Pharmaceuticals position peaked at $439K in Q3 2021.
247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Inspire Investing's 13F filing for Q4 2021, filed 3 Feb 2022.